Last 48 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.50 | 1.36 | 1.44 | 1.65 | 1.25 | 1.39 | 0.89 | 1.09 | 0.84 | 0.50 | 0.48 | 0.78 | 0.31 | 0.25 | 0.32 | 0.37 | 0.30 | 0.24 | 0.23 | 0.38 | 0.47 |
| — | -2.2% | +62.9% | +51.2% | +49.6% | +178.2% | +84.8% | +39.5% | +167.0% | +102.9% | +51.3% | +110.0% | +5.7% | +2.8% | +39.9% | -1.1% | -36.8% | -47.5% | -63.0% | -59.8% | -65.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.6% | -14.3% | -12.7% | -9.4% | -10.5% | -9.6% | -9.9% | -7.3% | -10.3% | -12.9% | -12.6% | -17.5% | -14.1% | -12.2% | -12.5% | -9.2% | -32.3% | -5.4% | -5.7% | -6.8% | -6.2% |
| — | -49.7% | -28.1% | -28.7% | -2.6% | +25.8% | +21.9% | +58.2% | +27.1% | -6.2% | -0.8% | -90.5% | +56.4% | -125.0% | -118.8% | -34.2% | -424.8% | +12.5% | +17.7% | +1.5% | -37.6% | |
| ROA | -29.4% | -13.0% | -11.8% | -8.9% | -9.8% | -8.8% | -9.2% | -6.8% | -9.3% | -11.5% | -11.2% | -15.1% | -12.2% | -10.7% | -11.2% | -8.2% | -29.8% | -5.1% | -5.4% | -6.4% | -5.8% |
| — | -48.3% | -28.1% | -30.1% | -5.5% | +23.3% | +18.0% | +54.9% | +24.1% | -6.7% | +0.0% | -83.2% | +59.0% | -111.9% | -107.5% | -27.8% | -414.0% | +13.1% | +19.4% | +5.4% | -32.2% | |
| ROIC | -60.9% | -13.1% | -11.1% | -9.2% | -10.5% | -9.2% | -13.2% | -26.5% | -49.3% | -43.8% | -84.8% | -39.0% | -19.9% | -15.1% | -13.3% | -8.9% | -32.5% | -5.5% | -5.2% | -6.1% | -5.7% |
| — | -42.1% | +16.4% | +65.2% | +78.8% | +79.0% | +84.4% | +32.1% | -147.1% | -189.5% | -538.4% | -338.5% | +38.6% | -174.2% | -156.7% | -45.6% | -469.0% | +6.1% | +27.1% | +51.2% | +74.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.06 | 0.05 | 0.09 | 0.08 | 0.07 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.05 | 0.04 |
| — | -37.5% | -37.7% | -36.7% | -36.2% | -52.3% | -49.5% | -70.2% | -66.5% | -21.9% | -22.2% | +37.7% | +28.0% | +56.2% | +48.5% | +40.8% | +39.9% | +8.6% | +9.4% | +715.0% | +719.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.58 | 9.01 | 10.97 | 15.69 | 14.58 | 13.69 | 12.82 | 18.03 | 15.71 | 9.85 | 16.33 | 10.53 | 11.17 | 11.49 | 17.09 | 14.76 | 15.01 | 26.59 | 28.94 | 31.70 | 21.66 |
| — | -34.2% | -14.4% | -13.0% | -7.2% | +39.0% | -21.5% | +71.3% | +40.6% | -14.3% | -4.4% | -28.7% | -25.6% | -56.8% | -41.0% | -53.4% | -30.7% | +2.5% | +20.9% | +19.7% | -62.7% | |
| Quick Ratio | 14.58 | 9.01 | 10.97 | 15.69 | 14.58 | 13.69 | 12.82 | 18.03 | 15.71 | 9.85 | 16.33 | 10.53 | 11.17 | 11.49 | 17.09 | 14.76 | 14.81 | 26.59 | 28.94 | 31.70 | 21.66 |
| — | -34.2% | -14.4% | -13.0% | -7.2% | +39.0% | -21.5% | +71.3% | +40.6% | -14.3% | -4.4% | -28.7% | -24.5% | -56.8% | -41.0% | -53.4% | -31.7% | +2.5% | +20.9% | +19.7% | -62.7% | |
| Interest Coverage | — | -15.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -93.38 | -27.07 | -23.68 | -25.23 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TARA stock.
Protara Therapeutics, Inc.'s current P/E is -1.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Protara Therapeutics, Inc.'s business trajectory between earnings reports.